Palomino Laboratories Inc. has 6 Schedule 13D or 13G filings on record since 2025-10-06. 4 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Shealy Jeffrey B. | 23.8% | 4,666,666 | SCHEDULE 13D, 2025-10-27 | 2025-09-29 |
| Lucius Partners LLC | 23% | 4,000,000 | SCHEDULE 13D/A, 2025-10-06 | 2025-09-29 |
| Steven DenBaars | 9.4% | 1,750,000 | SCHEDULE 13D, 2025-10-07 | 2025-09-29 |
| Richard Ogawa | 6.9% | 1,882,500 | SCHEDULE 13D/A, 2026-08-21 | 2026-07-31 |
Purpose of Transaction (Item 4)
Steven DenBaars
The Reporting Person acquired the Common Stock in connection with the Merger and the Offering. The information contained in Item 3 of this Schedule 13D is incorporated herein by reference. The Reporting Person serves as a director of the Issuer. Accordingly, the Reporting Person may have influence over the corporate activities of the Issuer, including activities that may relate to items described in clauses (a) through (j) of Item 4 of this Schedule 13D. Subject to the Lock-Up Agreement described in Item 6 of this Schedule 13D, the Reporting Person may, from time to time, purchase or sell securities of the Issuer as appropriate for his personal circumstances. Except as described in this Schedule 13D, the Reporting Person does not have any present plans or proposals that relate to or would result in any of the actions described in clauses (a) through (j) of Item 4 of this Schedule 13D. The Reporting Person reserves the right to formulate plans and/or proposals and to take such actions with respect to their investment in the Issuer, including any or all of the actions set forth in clauses (a) through (j) of Item 4 of this Schedule 13D.Item 4 of the SCHEDULE 13D filed 2025-10-07
Richard Ogawa
The Reporting Person acquired the Consideration Shares pursuant to the Share Exchange Agreement. The information contained in Item 3 of this Schedule 13D is incorporated herein by reference. The Reporting Person serves as the Secretary and a director of the Issuer. Accordingly, the Reporting Person may have influence over the corporate activities of the Issuer, including activities that may relate to items described in clauses (a) through (j) of Item 4 of this Schedule 13D. Except as described in this Schedule 13D, the Reporting Person does not have any present plans or proposals that relate to or would result in any of the actions described in clauses (a) through (j) of Item 4 of this Schedule 13D. The Reporting Person reserves the right to formulate plans and/or proposals and to take such actions with respect to their investment in the Issuer, including any or all of the actions set forth in clauses (a) through (j) of Item 4 of this Schedule 13D.Item 4 of the SCHEDULE 13D/A filed 2026-08-21
Shealy Jeffrey B.
The Reporting Person acquired the Common Stock in connection with the Merger and the Offering. The information contained in Item 3 of this Schedule 13D is incorporated herein by reference. The Reporting Person serves as the Chief Executive Officer, President and a director of the Issuer. Accordingly, the Reporting Person may have influence over the corporate activities of the Issuer, including activities that may relate to items described in clauses (a) through (j) of Item 4 of this Schedule 13D. Subject to the Lock-Up Agreement described in Item 6 of this Schedule 13D, the Reporting Person may, from time to time, purchase or sell securities of the Issuer as appropriate for his personal circumstances. Except as described in this Schedule 13D, the Reporting Person does not have any present plans or proposals that relate to or would result in any of the actions described in clauses (a) through (j) of Item 4 of this Schedule 13D. The Reporting Person reserves the right to formulate plans and/or proposals and to take such actions with respect to their investment in the Issuer, including any or all of the actions set forth in clauses (a) through (j) of Item 4 of this Schedule 13D.Item 4 of the SCHEDULE 13D filed 2025-10-27
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-10-06 | Lucius Partners LLC | 100% | SCHEDULE 13D |
| 2025-10-06 | Lucius Partners LLC | 23% | SCHEDULE 13D/A |
| 2025-10-07 | Steven DenBaars | 9.4% | SCHEDULE 13D |
| 2025-10-08 | Richard Ogawa | 9.4% | SCHEDULE 13D |
| 2025-10-27 | Shealy Jeffrey B. | 23.8% | SCHEDULE 13D |
| 2026-08-21 | Richard Ogawa | 6.9% | SCHEDULE 13D/A |
Palomino Laboratories Inc.: every filing and event
Tools for this story
Each opens in a new tab, filled in for Palomino Laboratories Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.